Yarrowia lipolytica causes sporadic cases and local outbreaks of infections and colonisation.
candidaemia
colonization
molecular typing
yarrowia lipolytica
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
22
11
2019
revised:
20
04
2020
accepted:
21
04
2020
pubmed:
27
4
2020
medline:
7
2
2021
entrez:
27
4
2020
Statut:
ppublish
Résumé
Yarrowia lipolytica belongs to the normal human microbiota but is also found in substrates with high contents in lipids and used in biotechnological processes. It is sometimes reported as human pathogen and especially in catheter-related candidaemia. Two apparently grouped cases of infections and/or contamination were reported involving 3 and 9 patients, respectively, in two hospitals. The goal of this study was to design a molecular tool to study the genetic diversity of Y lipolytica and confirm or not the common source of contamination during these grouped cases. Given that there is no genotyping method, we used genomic markers assessed on environmental isolates to determine intra-species relationship. We selected five highly polymorphic intergenic regions, totalling more than 3200 bp and sequenced them for clinical (n = 20) and environmental (n = 14) isolates. Antifungal susceptibility was determined by EUCAST broth microdilution method. Multiple alignment of the five sequences revealed divergence of 0%-5.8% between isolates as compared to approximately 0.2%-0.25% after alignment of whole genomes, suggesting their potential usefulness to establish genetic relatedness. The analysis showed the multiple origins of the isolates. It uncovered two grouped case of fungaemia involving 3 and 2 patients, respectively. It also revealed several unrelated sporadic cases despite their temporal relationship and one probable laboratory contamination by a common yet uncovered source, explaining several consecutive positive cultures without infection. All isolates had high minimal inhibitory concentration (MIC) for flucytosine, the majority (14/34) was susceptible to fluconazole, and all to the other antifungal agents tested. This method could help elucidate cases related to the opportunistic pathogen Y lipolytica.
Sections du résumé
BACKGROUND
BACKGROUND
Yarrowia lipolytica belongs to the normal human microbiota but is also found in substrates with high contents in lipids and used in biotechnological processes. It is sometimes reported as human pathogen and especially in catheter-related candidaemia.
OBJECTIVES
OBJECTIVE
Two apparently grouped cases of infections and/or contamination were reported involving 3 and 9 patients, respectively, in two hospitals. The goal of this study was to design a molecular tool to study the genetic diversity of Y lipolytica and confirm or not the common source of contamination during these grouped cases.
METHODS
METHODS
Given that there is no genotyping method, we used genomic markers assessed on environmental isolates to determine intra-species relationship. We selected five highly polymorphic intergenic regions, totalling more than 3200 bp and sequenced them for clinical (n = 20) and environmental (n = 14) isolates. Antifungal susceptibility was determined by EUCAST broth microdilution method.
RESULTS
RESULTS
Multiple alignment of the five sequences revealed divergence of 0%-5.8% between isolates as compared to approximately 0.2%-0.25% after alignment of whole genomes, suggesting their potential usefulness to establish genetic relatedness. The analysis showed the multiple origins of the isolates. It uncovered two grouped case of fungaemia involving 3 and 2 patients, respectively. It also revealed several unrelated sporadic cases despite their temporal relationship and one probable laboratory contamination by a common yet uncovered source, explaining several consecutive positive cultures without infection. All isolates had high minimal inhibitory concentration (MIC) for flucytosine, the majority (14/34) was susceptible to fluconazole, and all to the other antifungal agents tested.
CONCLUSION
CONCLUSIONS
This method could help elucidate cases related to the opportunistic pathogen Y lipolytica.
Substances chimiques
Antifungal Agents
0
Banques de données
GENBANK
['AF198090']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
737-745Subventions
Organisme : Santé Publique Fr
Organisme : ance
Organisme : Institut Pasteur
Organisme : Santé Publique France
Informations de copyright
© 2020 Blackwell Verlag GmbH.
Références
Franck R, Baluch A, Sandin R. Yarrowia lipolytica as normal human flora: a case series of 24 patients with positive cultures and no attributable disease. 48th Annual Meeting, Infectious Diseases Society of America; Vancouver, Canada. 2010.
Bremenkamp RM, Caris AR, Jorge AO, et al. Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus. Arch Oral Biol. 2011;56(6):549-555.
Hagler AN, Mendonca-Hagler LC Candida lipolytica isolated from Guanabara Bay and its ability to grow in marine and estuarine conditions. Revista brasileira de pesquisas medicas e biologicas. 1979;12(4-5):273-277.
Butinar L, Santos S, Spencer-Martins I, Oren A, Gunde-Cimerman N. Yeast diversity in hypersaline habitats. FEMS Microbiol Lett. 2005;244(2):229-234.
Kurtzman CP. Yarrowia van der Walt & von Arx (1980). In: Kurtzman CP, Fell JW, Boekhout T, eds. The Yeasts: a Taxonomic Study. 2. 5th ed. London, UK: Elsevier; 2011: 927-929.
Groenewald M, Boekhout T, Neuveglise C, Gaillardin C, van Dijck PW, Wyss M. Yarrowia lipolytica: safety assessment of an oleaginous yeast with a great industrial potential. Crit Rev Microbiol. 2014;40(3):187-206.
Liu HH, Ji XJ, Huang H. Biotechnological applications of Yarrowia lipolytica: Past, present and future. Biotechnol Adv. 2015;33(8):1522-1546.
Meunchan M, Michely S, Devillers H, Nicaud JM, Marty A, Neuveglise C. Comprehensive analysis of a yeast lipase family in the Yarrowia clade. PLoS ONE. 2015;10(11):e0143096.
Bourdichon F, Casaregola S, Farrokh C, et al. Food fermentations: microorganisms with technological beneficial use. Int J Food Microbiol. 2012;154(3):87-97.
EFSA Panel on Biological Hazards (BIOHAZ), Ricci A, Allende A, et al. Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 8: suitability of taxonomic units notified to EFSA until March 2018. EFSA J. 2018;16(7):5315.
D'Antonio D, Romano F, Pontieri E, et al. Catheter-related candidemia caused by Candida lipolytica in a patient receiving allogeneic bone marrow transplantation. J Clin Microbiol. 2002;40(4):1381-1386.
Liu WC, Chan MC, Lin TY, Hsu CH, Chiu SK. Candida lipolytica candidemia as a rare infectious complication of acute pancreatitis: a case report and literature review. J Microbiol Immunol Infect. 2013;46(5):393-396.
Wehrspann P, Fullbrandt U. Report of a case of Yarrowia lipolytica, (Wickerman et al.) van der Walt & von Arx isolated from a blood culture. Mykosen. 1985;28(5):217-222.
Abbes S, Amouri I, Trabelsi H, et al. Analysis of virulence factors and in vivo biofilm-forming capacity of Yarrowia lipolytica isolated from patients with fungemia. Med Mycol. 2016;55(2):193-202.
Zhao Y, Chan JF, Tsang CC, et al. Clinical characteristics, laboratory identification, and in vitro antifungal susceptibility of Yarrowia (Candida) lipolytica isolates causing Fungemia: a multicenter, prospective surveillance study. J Clin Microbiol. 2015;53(11):3639-3645.
Trabelsi H, Chtara K, Khemakhem N, et al. Fungemia caused by Yarrowia lipolytica. Mycopathologia. 2015;179(5-6):437-445.
Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366-1377.
Bretagne S, Renaudat C, Desnos-Ollivier M, et al. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002-14). J Antimicrob Chemother. 2017;72(6):1784-1793.
Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20(Suppl 3):76-98.
Desnos-Ollivier M, Robert V, Raoux-Barbot D, Groenewald M, Dromer F. Antifungal susceptibility profiles of 1698 yeast reference strains revealing potential emerging human pathogens. PLoS ONE. 2012;7(3):e32278.
Colombo AL, Junior JNA, Guinea J. Emerging multidrug-resistant Candida species. Curr Opin Infect Dis. 2017;30(6):528-538.
Dujon B, Sherman D, Fischer G, et al. Genome evolution in yeasts. Nature. 2004;430(6995):35-44.
Walker C, Ryu S, Na H, et al. Genome assemblies of five robust Yarrowia lipolytica strains exhibiting high lipid production, pentose sugar utilization, and sugar alcohol secretion from undetoxified lignocellulosic biomass hydrolysates. Microbiol Resour Announc. 2018;7(12):e01040.
Casaregola S, Neuveglise C, Lepingle A, et al. Genomic exploration of the hemiascomycetous yeasts: 17. Yarrowia lipolytica. FEBS Lett. 2000;487(1):95-100.
Magnan C, Yu J, Chang I, et al. Sequence assembly of Yarrowia lipolytica strain W29/CLIB89 shows transposable element diversity. PLoS ONE. 2016;11(9):e0162363.
Devillers H, Brunel F, Polomska X, et al. Genome sequence of Yarrowia lipolytica strain A-101 isolated from polluted soil in Poland. Genome Announc. 2016;4(5):e01094.
Liu L, Draft AHS. Genome sequence of the oleaginous yeast Yarrowia lipolytica PO1f, a commonly used metabolic engineering host. Genome Announc. 2014;2(4):e00652.
Devillers H, Neuveglise C. Genome sequence of the oleaginous yeast Yarrowia lipolytica H222. Microbiol Resour Announc. 2019;8(4):e01547.
Casaregola S, Feynerol C, Diez M, Fournier P, Gaillardin C. Genomic organization of the yeast Yarrowia lipolytica. Chromosoma. 1997;106(6):380-390.
de Hoog G, Gerrits van den Ende A. Molecular diagnostics of clinical strains of filamentous Basidiomycetes. Mycoses. 1998;41:183-189.
Masclaux F, Gueho E, de Hoog G, Christen R. Phylogenetic relationships of human-pathogenic Cladosporium (Xylohypha) species inferred from partial LS rRNA sequences. J Med Vet Mycol. 1995;33:327-338.
O’Donnell K. Fusarium and its near relatives. In: Reynolds D, Taylor J, eds. The Fungal Holomorph: Mitotic, Meiotic and Pleomorphic Speciation In Fungal Systematics. Wallingford, UK: CAB; 1993:225-233.
White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols: A Guide to Methods and Applications. New York, NY: Academic Press; 1990:315-322.
Sandhu GS, Kline BC, Stockman L, Roberts GD. Molecular probes for diagnosis of fungal infections. J Clin Microbiol. 1995;33(11):2913-2919.
Rutherford K, Parkhill J, Crook J, et al. Artemis: sequence visualization and annotation. Bioinformatics. 2000;16(10):944-945.
Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23(10):1289-1291.
Untergasser A, Cutcutache I, Koressaar T, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115.
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30(12):2725-2729.
Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W, Eucast A. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect. 2012;18(7):E246-E247.
Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27(6):484-492.